cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Viskasari P. Kalanjati
Contact Email
fmi@journal.unair.ac.id
Phone
-
Journal Mail Official
fmi@journal.unair.ac.id
Editorial Address
Folia Medica Indonesiana The Unit of Journal Consortium and Folia Medica Indonesiana Faculty of Medicine, Universitas Airlangga Jl. Prof. Dr. Moestopo No.47, Pacar Kembang, Kec. Tambaksari, Surabaya, Jawa Timur 60132, Indonesia
Location
Kota surabaya,
Jawa timur
INDONESIA
Folia Medica Indonesiana
Published by Universitas Airlangga
ISSN : 23558398     EISSN : 2599056X     DOI : https://doi.org/10.65346/2958-4515.2401
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Health Professions Medicine & Pharmacology Neuroscience
Folia Medica Indonesiana, as indicated by its name, focuses on publishing good quality articles about research and education on health science and medicine in Indonesia. However, due to the fast growth of science and knowledge in these fields, we also welcome submitted articles from around the world, especially the ones that contain related matters from lower-middle income countries. Folia Medica Indonesiana is an open-access, peer-reviewed journal that is published online at least four times a year. The scope covers various aspects of basic medical sciences includes anatomy, physiology, pathology, microbiology, pharmacology, and molecular medicine) and clinical medicine (covers specialties like internal medicine, surgery, pediatrics, oncology, psychiatry, etc). We highlight the pathology and potential treatment of metabolic syndromes and infectious diseases. Folia Medica Indonesiana also encourages the publication of articles about health education. The scope includes, but is not limited to, articles that emphasize on preventive education on certain diseases in a community, also research report of various materials and/or methods to develop medical education. We recognize the importance of this type of articles to be published alongside the assigned topic in each of our yearly issues, to provide our readers with updated information in medical sciences’ research and education simultaneously.
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 13 Documents
 1   2 
Search results for , issue "Vol. 53, No. 4" : 13 Documents clear
Shoe insole for eccentric activities on daily application prevents muscular damage and improves fasting blood glucose Abdullah, Ahmad; Kusuma, Herdianty; Asnar, Elyana; Purwanto, Bambang
Folia Medica Indonesiana Vol. 53, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The eccentric contraction has been proven to improve Glut-1 expression in muscle and fasting glucose levels in mice. The same eccentric contraction occurs in human being when walking or running while wearing high heels. Innovation on the eccentric contraction with high heels can be done by using a specific shoe insole. The design of the rear insole is made thicker than the front. The purpose of this study was to determine the effects of insole use specified for eccentric activities on daily work shoes on the skeletal muscle damage after wearing the specified insole. Skeletal muscle damage was measured based on sTnI level. This was experimental study with pretest-posttest design. The subjects involved were non-diabetic woman workers in Faculty of Medicine of Universitas Airlangga, and were divided into two groups. Each group represented group members who wore 5-degree and 10-degree insoles respectively. The angle used for the shoe insoles were 5° and 10° respectively. These insoles were worn on weekdays for one week. Blood was taken one day after the subjects stop wearing the insoles. Data results showed that the levels of fasting blood glucose (FBG) of subjects who wore the 10-degree insole had a value of p<0.05. The use of insole lead to decreased levels of fasting blood glucose (FBG). This study found that the sTnI levels in the 5-degree and 10-degree insole groups had no significant effect on troponin I skeletal muscle levels before and after treatment.
Case report: post esophagectomy esophageal reconstruction in esophageal injury due to caustic materials Danardono, Edwin
Folia Medica Indonesiana Vol. 53, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

The esophageal caustic injury is rare, but it requires precise and complex management. A variety of reconstruction techniques have been done, but despite the increasing volume, the incidence of complications is still relatively high. We reported the experience in our center in handling esophageal reconstruction in patients with caustic esophageal injury that caused oesophageal stricture between 2014-2017. This study used case series method with literature review. The results showed that between 2014-2017, there were 3 patients with caustic esophageal injury. All patients undergoing esophageal reconstruction surgery were included under conditions of malnutrition. Two were caused by HCl and the rest by NaOH. All patients underwent a resection of stricture segment of the esophagus, either using partial or total esophagectomy. Anastomosis leakage occurred in all cases, but improved with conservative treatment. The average length of hospitalization was 27 days. The intraoperative blood loss in patients ranged from 450-700 cc. In conclusion, proper preliminary management can provide approppiate preparation of the patients for definitive or reconstructive surgery, especially to avoid malnutrition. The ideal reconstruction still could not be established, and the rate of postoperative complications was still high. The length of patient hospitalization was also relatively long.
Comparison of chemotherapy response and adverse effects of double-platinum plus egfr-tki versus double-platinum alone on nslclc patients with disease progression and egfr-tki treatment Wulandari, Laksmi; Wiriansya, Edward Pandu
Folia Medica Indonesiana Vol. 53, No. 4
Publisher : Folia Medica Indonesiana

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

EGFR-TKI is the first-line therapy for EGFR-mutant patients. Nevertheless, patients will have disease progression (median PFS 10 – 12 months) due to resistance. The treatment options are still limited in developing countries for such cases, thus double-platinum chemotherapy is the next option. Although IMPRESS study reported no difference in terms of PFS and OS between double-platinum alone and double-platinum plus EGFR-TKI, several local studies reported benefit of continuing EGFR-TKI in combination with double-platinum chemotherapy (treatment beyond progression). This study aimed to compare chemotherapy effects of double-platinum plus EGFR-TKI versus double-platinum alone on patients with NSCLC progression after EGFR-TKI treatment. This was an analytical descriptive study using prospective cohort design, involving 30 patients with disease progression following EGFR-TKI treatment that met inclusion criteria in Dr. Soetomo Hospital. Subjects were divided into two groups: arm A (double-platinum plus EGFR-TKI) and arm B (double-platinum alone). Subjects were observed until 4 cycles of double-platinum chemotherapy. Subjective response (body weight and EQ5D questionnaire) was analyzed, chest CT scans were evaluated using RECIST criteria, and adverse effects were monitored. This study was conducted in accordance with GCP principles and has received ethics certificate from Dr. Soetomo Hospital ethics committee (No. 08/Panke.KKE/I/2017). The results showed that subject characteristics between two arms were insignificantly different (p=0.05). The most common EGFR mutation was exon 21 (50% on arm A and 60% on arm B). Chi square was tested on subjective response parameter (EQ5D (p=0.483)). T2 free sample was tested on semi-subjective parameter (body weight (p=1.00)). Comparison test on both groups after cycle 2 and 4 showed p value=0.05. Statistical test on adverse effect between both groups showed p value=0.526. As a conclusion, there was no significant difference between double-platinum and double-platinum plus EGFR-TKI on patients who had disease progression following EGFR-TKI treatment.

Page 2 of 2 | Total Record : 13

 1   2 

Filter by Year

2017 2017


Reset
Filter By Issues
All Issue Vol. 61, No. 2 Vol. 61, No. 1 Vol. 60, No. 4 Vol. 60, No. 3 Vol. 60, No. 2 Vol. 60, No. 1 Vol. 59, No. 4 Vol. 59, No. 3 Vol. 59, No. 2 Vol. 59, No. 1 Vol. 58, No. 4 Vol. 58, No. 3 Vol. 58, No. 2 Vol. 58, No. 1 Vol. 57, No. 4 Vol. 57, No. 3 Vol. 57, No. 2 Vol. 57, No. 1 Vol. 56, No. 4 Vol. 56, No. 3 Vol. 56, No. 2 Vol. 56, No. 1 Vol. 55, No. 4 Vol. 55, No. 3 Vol. 55, No. 2 Vol. 55, No. 1 Vol. 54, No. 4 Vol. 54, No. 3 Vol. 54, No. 2 Vol. 54, No. 1 Vol. 53, No. 4 Vol. 53, No. 3 Vol. 53, No. 2 Vol. 53, No. 1 Vol. 52, No. 4 Vol. 52, No. 3 Vol. 52, No. 2 Vol. 52, No. 1 Vol. 51, No. 4 Vol. 51, No. 3 More Issue